Recently, CGeneTech (Suzhou, China) Co., Ltd. and Medicilon Biomedical Co., Ltd. have successfully reached a strategic cooperation on PROTAC project. In this collaboration, CGeneTech will use the proven technology provided by Medicilon with PROTAC technology as the core technology. Unlike the traditional drug development concept of inhibiting the activity or function of disease-causing proteins, PROTAC (proteolysis-targeting chimera) therapy uses the natural mechanism of proteins in cells to degrade disease-causing target proteins in order to intervene or treat diseases.

Dr. Qiang Yu and Dr. Feng Ren complete the contract online

Medicilon Chemistry has summarized the current popular target protein ligands and established an extensive library of highly affinity small molecules and small molecule fragments of popular target proteins compounds (TPSM), an extensive linker system of E3 ligase highly affinity small molecules and small molecule fragments (E3SM) and bifunctional linkers (BF-Linker) with a wide diversity of On this basis, we have successfully constructed a series of PROTAC protein degradation targeting chimeras, which greatly enhance the drug discovery process using PROTAC technology.

Medixi has also established and perfected the PROTAC biological screening and testing platform. The Biology Department has mature PROTAC functional assay and validation technology, and has established a high-throughput PROTAC screening platform using fusion protein expression and BiFC (Dual Fluorescence Molecular Complementation) technology to screen PROTAC small molecules for targeted degradation of disease-causing proteins.

At the end of the meeting, Dr. Qiang Yu, CEO of CGeneTech, wrote a poem to express his hopes and wishes for the future collaboration project.

The peak is like an axe.

Mountains open cliffs stand.

There is no time for leisurely clouds RaO,

Climbing to the top with the sky T.

The dream of the prosperous world is mA.

Tongcheng Medi C!

About CGeneTech

CGeneTech (Suzhou, China) Co., Ltd. is a high-tech enterprise dedicated to the research, development, production and sales of small molecule innovative drugs. Since its establishment, the company has applied for several invention patents and has been granted 2 patents. Among them, Shengliptin, a new class 1.1 hypoglycemic drug, has been successfully selected for the National 12th Five-Year Plan and 13th Five-Year Plan "Major New Drug Creation", and has been included in the track of key support for innovative drugs at the national level. Preclinical studies have shown that the key technical parameters and long-term benefits of Shengliptin are significantly better than those of its global counterpart, selegiline, and clinical approval was obtained from the State Drug Administration in 2017. Centigliptin's flash release formulation technology was also awarded the title of Suzhou Engineering Center, on which the special formulation new drug project represented by Asenapine was developed, and more new class 2 improved drugs will be developed on this platform in the future.

About Medicilon

Founded in 2004 and headquartered in Shanghai, Medicilon (stock code: 688202) is dedicated to providing a full range of preclinical new drug research services to pharmaceutical companies, research institutions and researchers worldwide. Medici's one-stop integrated services help clients accelerate their drug discovery process with strong project management and more efficient and cost-effective R&D services, covering the entire preclinical drug discovery process, including drug discovery, pharmacology and preclinical studies. Medixi has grown with domestic and international quality clients, providing new drug development services to more than 700 clients worldwide. Medixi will continue to contribute to human health with a global vision and focus on innovation in China!